AZNAstraZenecaRunning, no new patients
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Unresectable Locally Advanced Urothelial Cancer · Metastatic Urothelial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,246 (final count)
- Started
- Sep 27, 2018
- Main results expected
- Jun 1, 2026
- Fully finished
- Jun 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03682068 · record last updated 2026-08-20 · checked 2026-11-09 15:47 UTC